Illumina (ILMN) Expected to Announce Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMN) is anticipated to release its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect Illumina to post earnings of $1.22 per share and revenue of $1.0997 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Illumina Stock Down 4.0%

NASDAQ:ILMN opened at $135.43 on Wednesday. Illumina has a one year low of $68.70 and a one year high of $155.53. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The company has a market cap of $20.69 billion, a PE ratio of 30.37, a P/E/G ratio of 2.34 and a beta of 1.45. The firm’s 50 day simple moving average is $138.50 and its 200 day simple moving average is $115.74.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Sivia Capital Partners LLC purchased a new position in Illumina during the second quarter valued at $621,000. Blair William & Co. IL raised its stake in shares of Illumina by 16.1% in the third quarter. Blair William & Co. IL now owns 3,002 shares of the life sciences company’s stock worth $285,000 after buying an additional 416 shares during the period. Evergreen Capital Management LLC purchased a new position in shares of Illumina during the 2nd quarter valued at about $271,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in shares of Illumina during the 2nd quarter valued at approximately $320,000. Finally, CW Advisors LLC purchased a new stake in Illumina in the 2nd quarter worth approximately $275,000. 89.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ILMN. JPMorgan Chase & Co. upped their price objective on shares of Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. UBS Group upped their price target on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Robert W. Baird set a $109.00 price objective on Illumina in a research report on Friday, October 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Finally, Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Six investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $127.18.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.